Published On: Wed, Oct 19th, 2016

Idera Pharmaceuticals, Inc. (IDRA) Latest Broker Coverage


A number of investment brokers have recently updated their price targets on shares of Idera Pharmaceuticals, Inc. (IDRA).

Most recent broker ratings

08/25/2016 – Idera Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 6 price target on the stock.

12/07/2015 – Idera Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray. They now have a USD 7 price target on the stock.

11/25/2015 – Idera Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen.

06/15/2015 – JP Morgan began new coverage on Idera Pharmaceuticals, Inc. giving the company a “overweight” rating. They now have a USD 6 price target on the stock.

05/13/2015 – Idera Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Zacks.

03/28/2014 – Idera Pharmaceuticals, Inc. was downgraded to “sell” by analysts at TheStreet.

The share price of Idera Pharmaceuticals, Inc. (IDRA) was up +0.57% during the last day of trading, with a day high of 1.79. 1103476 shares were traded during the last session.

The stock’s 50 day moving average is 2.18 and its 200 day moving average is 1.81. The stock’s market capitalization is 212.41M. Idera Pharmaceuticals, Inc. has a 52-week low of 1.19 and a 52-week high of 4.42.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.